| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.8 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.018 | 0.8 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.8 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.8 |
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.8 |